1.Kaposi’s Sarcoma in a patient living with HIV: A case report
Unenchimeg P ; ; Uugan-Oyun Ch ; Narantuya P ; Oyunjargal M ; Indra A ; Narmandakh O
Mongolian Journal of Health Sciences 2026;94(4):154-156
Background:
People living with human immunodeficiency virus (HIV) are at increased risk of developing opportunistic infections and malignancies due to immunosuppression. Among these, Kaposi’s sarcoma (KS) and lymphoma are malignant conditions affecting mucocutaneous tissues and are considered multifocal angioproliferative disorders, as originally described by Moritz Kaposi. These conditions are more likely to occur in individuals with uncontrolled viral replication and low CD4 cell counts. In Mongolia, although the overall prevalence of HIV infection remains low and early initiation of antiretroviral therapy (ART) has reduced the incidence of opportunistic infections, cases of AIDS-related malignancies continue to be reported. Therefore, evaluating the clinical presentation, diagnosis, and treatment outcomes of malignancies in HIV-infected patients is of significant importance.
Aim:
To present a case of Kaposi’s sarcoma in a patient living with HIV in Mongolia, and to describe the clinical course, diagnostic findings, treatment outcomes, and the impact of antiretroviral therapy (ART).
Materials and Methods:
This case report is based on a descriptive analysis of a single patient. Clinical data, including medical history, physical examination findings, laboratory parameters (CD4 cell count and viral load), imaging studies, histopathological results, treatment course, and outcomes were collected from the medical records of the National Center for Communicable Diseases and analyzed qualitatively.
Case Presentation:
A 35-year-old male patient presented with oral lesions that first appeared in June 2010 and progressively increased in number and size. In July 2010, he underwent computed tomography (CT), magnetic resonance imaging (MRI), and histopathological examination in the Republic of Korea, which confirmed the diagnosis of Kaposi’s sarcoma and lymphosarcoma. The patient was enrolled in care at the National Center for Communicable Diseases on September 2, 2010. According to his history, he had lived in Taiwan for the past 10 years and reported having sex with men. On October 22, 2010, his CD4 cell count was 282 cells/ml and viral load was 210,000 copies/ml. Antiretroviral therapy (tenofovir/lamivudine/efavirenz) was initiated. Between 2010 and 2011, he received six cycles of chemotherapy (DOX, CTX, VCR), and surgical excision of skin lesions was performed. Following treatment, the Kaposi’s sarcoma and lymphosarcoma lesions regressed significantly. By August 31, 2012, his CD4 cell count had increased to 535 cells/µL.
Conclusion
This case demonstrates that HIV-infected patients are at high risk of developing AIDS-defining malignancies due to immunosuppression. Early initiation of antiretroviral therapy (ART) played a crucial role in immune restoration, as evidenced by the increase in CD4 cell count. In addition, combined treatment with chemotherapy contributed to tumor regression and clinical improvement.
2.Associations of XRCC1 S326C (rs25487) gene Polymorphism in Myelodysplastic syndrome
Undarmaa O ; Narmandakh B ; Avirmed Kh ; Khosbayar T ; Odgerel Ts ; Batchimeg N
Health Laboratory 2017;7(2):21-25
Introduction:
Base excision repair (BER) is mainly responsible for the correction of small base changes of DNA damage. BER pathway involved many enzymes including OGG1 and XRCC1. The defective DNA repair is associated with an increased risk of various cancers including hematologic malignancies-leukemia and myelodysplastic syndrome (MDS). However, it is deniably these polymorphisms alter the susceptibility and clinical outcome of MDS patients.
The aim:
This study was to evaluate the impact of polymorphisms in gene encoding one protein of BER system: XRCC1 Arg399Gln in MDS and healthy population.
Methods:
In this study, we recruited 60 health control group [median 47.9 years, 9 MDS subjects [median 56.6 years] were included in this study. Genotyping was carried out by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. Allele and genotype frequencies were calculated by direct counting.
Result:
The frequencies of genotypes of XRCC1 Arg399Gln were as follows: Arg /Arg 1 (11%), Arg/Gln 6 (66%), Gln/Gln 2 (22%) in MDS and Arg /Arg 18.4%, Arg/Gln40%, Gln/Gln41.6% in health control for XRCC1 Arg399Gln. The result revealed that genotypes Arg399Gln increased the risk of MDS
In conclusion
this study is the first to analyze XRCC1 SNPs and their associated risk of MDS in Mongolian samples. To fully understand the role of DNA damage and DNA repair in the MDS, prospective studies are needed and other genes (OGG1 Ser326Cys, MUTYH Gln324His, APE Asp148Glu) of base excision repair pathway should be analyzed.
Result Analysis
Print
Save
E-mail